Naturally acquired antibodies specific for plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria

Journal of Infectious Diseases

Volumn 209, Issue 5, 2014, Pages 789-798

  Tran, Tuan M ^a   Ongoiba, Aissata ^b   Coursen, Jill ^a   Crosnier, Cecile ^c   Diouf, Ababacar ^a   Huang, Chiung Yu ^d   Li, Shanping ^a   Doumbo, Safiatou ^b   Doumtabe, Didier ^b   Kone, Younoussou ^b   Bathily, Aboudramane ^b   Dia, Seydou ^b   Niangaly, Moussa ^b   Dara, Charles ^b   Sangala, Jules ^b   Miller, Louis H ^a   Doumbo, Ogobara K ^b   Kayentao, Kassoum ^b   Long, Carole A ^a   Miura, Kazutoyo ^a   Wright, Gavin J ^c   Traore, Boubacar ^b   Crompton, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Sociétés   (Mali)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

blood stage immunity; endemic population; malaria; Plasmodium falciparum; prospective cohort study; RH5

Indexed keywords

BLOOD-STAGE IMMUNITY; ENDEMIC POPULATION; MALARIA; PLASMODIUM FALCIPARUM; PROSPECTIVE COHORT STUDY; RH5;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLACENTA; PLASMODIUM FALCIPARUM; PREGNANCY; RETICULOCYTES; YOUNG ADULT;

EID: 84894289219     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit553     Document Type: Article

References (48)

1. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413-31.
2. World Health Organization. World malaria report 2012. Geneva, Switzerland: WHO, 2012.
3. Miotto O, Almagro-Garcia J, Manske M, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 2013; 45:648-55.
4. Ranson H, N'Guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol 2011; 27:91-8.
5. Butler NS, Vaughan AM, Harty JT, Kappe SH. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol 2012; 33:247-54.
6. maIERAConsultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med 2011; 8:e1000398.
7. Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011; 365:1004-13.
8. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria.' Parasite Immunol 2009; 31:560-73.
9. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006; 124:755-66.
10. Hayton K, Gaur D, Liu A, et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 2008; 4:40-51.
11. Baum J, Chen L, Healer J, et al. Reticulocyte-binding protein homologue 5-an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol 2009; 39:371-80.
12. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011; 480:534-7.
13. Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2011; 2:601.
14. Williams AR, Douglas AD, Miura K, et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog 2012; 8:e1002991.
15. Bustamante LY, Bartholdson SJ, Crosnier C, et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 2013; 31:373-9.
16. Miller LH, Roberts T, Shahabuddin M, McCutchan TF. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 1993; 59:1-14.
17. Ferreira MU, Ribeiro WL, Tonon AP, Kawamoto F, Rich SM. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 2003; 304:65-75.
18. Duan J, Mu J, Thera MA, et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci USA 2008; 105: 7857-62.
19. Takala SL, Coulibaly D, Thera MA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2009; 1:2ra5.
20. Manske M, Miotto O, Campino S, et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 2012; 487:375-9.
21. Tran TM, Li S, Doumbo S, et al. An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis 2013; 57:40-7.
22. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHOVitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009; 12:444-54.
23. Bushell KM, Sollner C, Schuster-Boeckler B, Bateman A, Wright GJ. Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res 2008; 18:622-30.
24. Miura K, Zhou H, Moretz SE, et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 2008; 181:8776-83.
25. Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73:3677-85.
26. Shaukat AM, Gilliams EA, Kenefic LJ, et al. Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malar J 2012; 11:207.
27. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA 2010; 107:6958-63.
28. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994; 1:667-9.
29. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009; 77:1165-74.
30. Tongren JE, Drakeley CJ, McDonald SL, et al. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun 2006; 74:257-64.
31. Bousema T, Kreuels B, Gosling R. Adjusting for heterogeneity of malaria transmission in longitudinal studies. J Infect Dis 2011; 204: 1-3.
32. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. (Statistics for biology and health). New York: Springer, 2000.
33. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
34. Miura K, Zhou H, Muratova OV, et al. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 2007; 75: 5827-36.
35. Persson KE, McCallum FJ, Reiling L, et al. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest 2008; 118:342-51.
36. Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76:2240-8.
37. Richards JS, Stanisic DI, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 2010; 51:e50-60.
38. Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013; 191:795-809.
39. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 2010; 7:e1000218.
40. Polley SD, Mwangi T, Kocken CH, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004; 23:718-28.
41. Crompton PD, Traore B, Kayentao K, et al. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis 2008; 198:1265-75.
42. Greenhouse B, Ho B, Hubbard A, et al. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 2011; 204:19-26.
43. Kun JF, Missinou MA, Lell B, et al. New emerging Plasmodium falciparum genotypes in children during the transition phase from asymptomatic parasitemia to malaria. Am J Trop Med Hyg 2002; 66:653-8.
44. Patel SD, Ahouidi AD, Bei AK, et al. Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J Infect Dis 2013; 208:1679-87.
45. Miura K, Zhou H, Diouf A, et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surfaceprotein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 2009; 16:963-8.
46. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185:820-7.
47. Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in western Kenya. PLoS One 2009; 4:e4708.
48. Chen L, Lopaticki S, Riglar DT, et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog 2011; 7:e1002199.